Organogenesis (NASDAQ:ORGO) Rating Increased to Sell at Wall Street Zen

Organogenesis (NASDAQ:ORGO) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday.

A number of other equities analysts have also issued reports on the company. BTIG Research lowered Organogenesis from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. UBS Group set a $3.00 target price on Organogenesis in a research note on Thursday, May 28th. Truist Financial initiated coverage on Organogenesis in a research report on Thursday, May 28th. They set a “hold” rating and a $3.00 price target for the company. Finally, Weiss Ratings cut Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Organogenesis has an average rating of “Hold” and an average target price of $5.75.

Organogenesis Stock Performance

Organogenesis stock opened at $2.44 on Friday. Organogenesis has a 52-week low of $2.04 and a 52-week high of $7.08. The company has a quick ratio of 3.16, a current ratio of 3.53 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $313.98 million, a price-to-earnings ratio of -12.84 and a beta of 1.32. The firm has a 50-day moving average price of $2.46 and a two-hundred day moving average price of $3.36.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.08). Organogenesis had a negative net margin of 0.84% and a positive return on equity of 9.63%. The firm had revenue of $37.23 million during the quarter, compared to analyst estimates of $43.26 million.

Hedge Funds Weigh In On Organogenesis

Hedge funds have recently modified their holdings of the company. First Light Asset Management LLC raised its stake in shares of Organogenesis by 10.6% in the 3rd quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company’s stock worth $31,641,000 after buying an additional 720,748 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Organogenesis by 14.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 5,535,334 shares of the company’s stock valued at $28,673,000 after buying an additional 680,392 shares in the last quarter. Deutsche Bank AG grew its holdings in Organogenesis by 0.4% during the fourth quarter. Deutsche Bank AG now owns 3,297,631 shares of the company’s stock worth $17,082,000 after acquiring an additional 13,301 shares during the period. Dimensional Fund Advisors LP grew its holdings in Organogenesis by 5.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,891,006 shares of the company’s stock worth $6,851,000 after acquiring an additional 160,026 shares during the period. Finally, Geode Capital Management LLC raised its position in Organogenesis by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 1,786,978 shares of the company’s stock worth $9,259,000 after acquiring an additional 62,346 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.